
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3EAuthor Manuscript%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Potent Kinetic Stabilizers that Prevent Transthyretin-mediated Cardiomyocyte Proteotoxicity - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="ABCB6E71925ECB733D6E71000E6B4369.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="nihpa">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="manuscript">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3227540/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Science translational medicine">
<meta name="citation_title" content="Potent Kinetic Stabilizers that Prevent Transthyretin-mediated Cardiomyocyte Proteotoxicity">
<meta name="citation_author" content="Mamoun M Alhamadsheh">
<meta name="citation_author_institution" content="Department of Pathology, Stanford University Medical School, Stanford, California, USA">
<meta name="citation_author_institution" content="Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California, USA">
<meta name="citation_author" content="Stephen Connelly">
<meta name="citation_author_institution" content="Department of Molecular Biology, The Scripps Research Institute, La Jolla, California, USA">
<meta name="citation_author" content="Ahryon Cho">
<meta name="citation_author_institution" content="Department of Pathology, Stanford University Medical School, Stanford, California, USA">
<meta name="citation_author" content="Natàlia Reixach">
<meta name="citation_author_institution" content="Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA">
<meta name="citation_author" content="Evan T Powers">
<meta name="citation_author_institution" content="Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA">
<meta name="citation_author_institution" content="Department of Chemistry, The Scripps Research Institute, La Jolla, California, USA">
<meta name="citation_author_institution" content="The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA">
<meta name="citation_author" content="Dorothy W Pan">
<meta name="citation_author_institution" content="Department of Pathology, Stanford University Medical School, Stanford, California, USA">
<meta name="citation_author" content="Ian A Wilson">
<meta name="citation_author_institution" content="Department of Molecular Biology, The Scripps Research Institute, La Jolla, California, USA">
<meta name="citation_author_institution" content="The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA">
<meta name="citation_author" content="Jeffery W Kelly">
<meta name="citation_author_institution" content="Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA">
<meta name="citation_author_institution" content="Department of Chemistry, The Scripps Research Institute, La Jolla, California, USA">
<meta name="citation_author_institution" content="The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA">
<meta name="citation_author" content="Isabella A Graef">
<meta name="citation_author_institution" content="Department of Pathology, Stanford University Medical School, Stanford, California, USA">
<meta name="citation_publication_date" content="2011 Aug 24">
<meta name="citation_volume" content="3">
<meta name="citation_issue" content="97">
<meta name="citation_firstpage" content="97ra81">
<meta name="citation_doi" content="10.1126/scitranslmed.3002473">
<meta name="citation_pmid" content="21865539">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC3227540/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC3227540/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC3227540/pdf/nihms337580.pdf">
<meta name="description" content="The V122I mutation that alters the stability of transthyretin (TTR) affects 3–4% of African Americans and leads to amyloidogenesis and development of cardiomyopathy. In addition, 10–15% of individuals over the age of 65 develop senile systemic ...">
<meta name="og:title" content="Potent Kinetic Stabilizers that Prevent Transthyretin-mediated Cardiomyocyte Proteotoxicity">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="The V122I mutation that alters the stability of transthyretin (TTR) affects 3–4% of African Americans and leads to amyloidogenesis and development of cardiomyopathy. In addition, 10–15% of individuals over the age of 65 develop senile systemic ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC3227540/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="3227540">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1126/scitranslmed.3002473"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/nihms337580.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC3227540%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/3227540/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/3227540/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC3227540/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-nihpa.png" alt="NIHPA Author Manuscripts logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to NIHPA Author Manuscripts" title="Link to NIHPA Author Manuscripts" shape="default" href="https://www.hhs.gov/open/public-access-guiding-principles/index.html" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Sci Transl Med</button></div>. Author manuscript; available in PMC: 2012 Aug 24.</div>
<div>
<em>Published in final edited form as: </em>Sci Transl Med. 2011 Aug 24;3(97):97ra81. doi: <a href="https://doi.org/10.1126/scitranslmed.3002473" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1126/scitranslmed.3002473</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22Sci%20Transl%20Med%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sci%20Transl%20Med%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Sci%20Transl%20Med%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Sci%20Transl%20Med%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Potent Kinetic Stabilizers that Prevent Transthyretin-mediated Cardiomyocyte Proteotoxicity</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alhamadsheh%20MM%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Mamoun M Alhamadsheh</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Mamoun M Alhamadsheh</span></h3>
<div class="p">
<sup>1</sup>Department of Pathology, Stanford University Medical School, Stanford, California, USA</div>
<div class="p">
<sup>6</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alhamadsheh%20MM%22%5BAuthor%5D" class="usa-link"><span class="name western">Mamoun M Alhamadsheh</span></a>
</div>
</div>
<sup>1,</sup><sup>6,</sup><sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Connelly%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Stephen Connelly</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Stephen Connelly</span></h3>
<div class="p">
<sup>2</sup>Department of Molecular Biology, The Scripps Research Institute, La Jolla, California, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Connelly%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Stephen Connelly</span></a>
</div>
</div>
<sup>2,</sup><sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cho%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Ahryon Cho</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Ahryon Cho</span></h3>
<div class="p">
<sup>1</sup>Department of Pathology, Stanford University Medical School, Stanford, California, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cho%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Ahryon Cho</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Reixach%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Natàlia Reixach</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Natàlia Reixach</span></h3>
<div class="p">
<sup>3</sup>Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Reixach%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Natàlia Reixach</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Powers%20ET%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Evan T Powers</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Evan T Powers</span></h3>
<div class="p">
<sup>3</sup>Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA</div>
<div class="p">
<sup>4</sup>Department of Chemistry, The Scripps Research Institute, La Jolla, California, USA</div>
<div class="p">
<sup>5</sup>The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Powers%20ET%22%5BAuthor%5D" class="usa-link"><span class="name western">Evan T Powers</span></a>
</div>
</div>
<sup>3,</sup><sup>4,</sup><sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pan%20DW%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Dorothy W Pan</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Dorothy W Pan</span></h3>
<div class="p">
<sup>1</sup>Department of Pathology, Stanford University Medical School, Stanford, California, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pan%20DW%22%5BAuthor%5D" class="usa-link"><span class="name western">Dorothy W Pan</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wilson%20IA%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Ian A Wilson</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Ian A Wilson</span></h3>
<div class="p">
<sup>2</sup>Department of Molecular Biology, The Scripps Research Institute, La Jolla, California, USA</div>
<div class="p">
<sup>5</sup>The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wilson%20IA%22%5BAuthor%5D" class="usa-link"><span class="name western">Ian A Wilson</span></a>
</div>
</div>
<sup>2,</sup><sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kelly%20JW%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Jeffery W Kelly</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Jeffery W Kelly</span></h3>
<div class="p">
<sup>3</sup>Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA</div>
<div class="p">
<sup>4</sup>Department of Chemistry, The Scripps Research Institute, La Jolla, California, USA</div>
<div class="p">
<sup>5</sup>The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kelly%20JW%22%5BAuthor%5D" class="usa-link"><span class="name western">Jeffery W Kelly</span></a>
</div>
</div>
<sup>3,</sup><sup>4,</sup><sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Graef%20IA%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Isabella A Graef</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Isabella A Graef</span></h3>
<div class="p">
<sup>1</sup>Department of Pathology, Stanford University Medical School, Stanford, California, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Graef%20IA%22%5BAuthor%5D" class="usa-link"><span class="name western">Isabella A Graef</span></a>
</div>
</div>
<sup>1,</sup><sup>*</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="A1">
<sup>1</sup>Department of Pathology, Stanford University Medical School, Stanford, California, USA</div>
<div id="A2">
<sup>2</sup>Department of Molecular Biology, The Scripps Research Institute, La Jolla, California, USA</div>
<div id="A3">
<sup>3</sup>Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA</div>
<div id="A4">
<sup>4</sup>Department of Chemistry, The Scripps Research Institute, La Jolla, California, USA</div>
<div id="A5">
<sup>5</sup>The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA</div>
<div id="A6">
<sup>6</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California, USA</div>
<div class="author-notes p">
<div class="fn" id="FN1">
<sup>*</sup><p class="display-inline">
To whom correspondence should be addressed. <span>igraef@stanford.edu</span></p>
</div>
<div class="fn" id="FN2">
<sup>7</sup><p class="display-inline">These authors contributed equally to this work.</p>
</div>
</div>
</div>
<div id="clp_a" class="d-panel p" style="display: none"><div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div></div>
</div>
<div>PMCID: PMC3227540  NIHMSID: NIHMS337580  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/21865539/" class="usa-link">21865539</a>
</div>
<div class="ra xbox p" role="complementary" aria-label="Related or updated information about this article"><div>The publisher's version of this article is available at <a href="https://doi.org/10.1126/scitranslmed.3002473" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Sci Transl Med</a>
</div></div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p id="P1">The V122I mutation that alters the stability of transthyretin (TTR) affects 3–4% of African Americans and leads to amyloidogenesis and development of cardiomyopathy. In addition, 10–15% of individuals over the age of 65 develop senile systemic amyloidosis (SSA) and cardiac TTR deposits due to wild-type TTR amyloidogenesis. As no approved therapies for TTR amyloid cardiomyopathy are available, the development of drugs that prevent amyloid-mediated cardiotoxicity is desired. To this aim, we developed a fluorescence polarization-based HTS screen, which identified several new chemical scaffolds targeting TTR. These novel compounds were potent kinetic stabilizers of TTR and prevented tetramer dissociation, unfolding and aggregation of both wild type and the most common cardiomyopathy-associated TTR mutant, V122I-TTR. High-resolution co-crystal structures and characterization of the binding energetics revealed how these diverse structures bound to tetrameric TTR. Our study also showed that these compounds effectively inhibited the proteotoxicity of V122I-TTR towards human cardiomyocytes. Several of these ligands stabilized TTR in human serum more effectively than diflunisal, which is one of the best known inhibitors of TTR aggregation, and may be promising leads for the treatment and/or prevention of TTR-mediated cardiomyopathy.</p></section><section id="S1"><h2 class="pmc_sec_title">INTRODUCTION</h2>
<p id="P2">The misassembly of soluble proteins into toxic amyloid aggregates underlies a large number of human degenerative diseases (<a href="#R1" class="usa-link" aria-describedby="R1">1</a>–<a href="#R3" class="usa-link" aria-describedby="R3">3</a>). TTR is one of more than 30 human amyloidogenic proteins whose misassembly can cause a variety of degenerative gain-of-toxic-function diseases. TTR is a tetrameric protein (54 kDa), secreted from the liver into the blood where, using orthogonal sites, it transports thyroxine (T<sub>4</sub>) and holo-retinol binding protein (<a href="#R4" class="usa-link" aria-describedby="R4">4</a>). However, 99% of the TTR T<sub>4</sub> binding sites remain unoccupied in humans owing to the presence of two other T<sub>4</sub> transport proteins in blood (<a href="#R3" class="usa-link" aria-describedby="R3">3</a>). Familial TTR amyloid diseases, which are associated with one of more than 80 mutations in the TTR gene, include the systemic neuropathies (familial amyloid polyneuropathy [FAP]), cardiomyopathies (familial amyloid cardiomyopathy [FAC]), and central nervous system amyloidoses (CNSA) (<a href="#R5" class="usa-link" aria-describedby="R5">5</a>–<a href="#R8" class="usa-link" aria-describedby="R8">8</a>).</p>
<p id="P3">Cardiac amyloidosis is most commonly caused by deposition of immunoglobulin light chains or TTR in the cardiac interstitium and conducting system. It is a chronic and progressive condition, which can lead to arrhythmias, biventricular heart failure, and death (<a href="#R8" class="usa-link" aria-describedby="R8">8</a>–<a href="#R10" class="usa-link" aria-describedby="R10">10</a>). Two types of TTR-associated amyloid cardiomyopathies are clinically important. Wild-type (WT) TTR aggregation underlies the development of senile systemic amyloidosis (SSA). Cardiac TTR deposits can be found in 10 to 15% of the population over the age of 65 at autopsy (<a href="#R10" class="usa-link" aria-describedby="R10">10</a>,<a href="#R11" class="usa-link" aria-describedby="R11">11</a>). Many of these patients are asymptomatic, but there is little doubt that SSA is an underdiagnosed disease. In addition, a number of TTR mutations, including V122I, lead to amyloidogenesis and familial amyloid cardiomyopathy (FAC) (<a href="#R12" class="usa-link" aria-describedby="R12">12</a>–<a href="#R15" class="usa-link" aria-describedby="R15">15</a>). Population studies show that the V122I mutation is found in 3–4% of African Americans (~1.3 million people) and contributes to the increased prevalence of heart failure among this population segment (<a href="#R14" class="usa-link" aria-describedby="R14">14</a>,<a href="#R15" class="usa-link" aria-describedby="R15">15</a>). The mutant TTR allele behaves as an autosomal dominant allele with age-dependent penetrance and the frequency of cardiac amyloidosis from TTR in African-American individuals above age 60 is four times that seen in Caucasian-Americans of comparable age.</p>
<p id="P4">All of the TTR mutations associated with familial amyloidosis decrease tetramer stability, and some decrease the kinetic barrier for tetramer dissociation (<a href="#R3" class="usa-link" aria-describedby="R3">3</a>, <a href="#R16" class="usa-link" aria-describedby="R16">16</a>). The latter is important because tetramer dissociation is the rate-limiting step in the TTR amyloidogenesis cascade (<a href="#R3" class="usa-link" aria-describedby="R3">3</a>). Kinetic stabilization of the native, tetrameric structure of TTR by interallelic trans suppression (incorporation of mutant subunits that raise the dissociative transition state energy) prevents post-secretory dissociation and aggregation, as well as the related disease familial amyloid polyneuropathy (FAP), by slowing TTR tetramer dissociation (<a href="#R17" class="usa-link" aria-describedby="R17">17</a>). Occupancy of the TTR T<sub>4</sub> binding sites with rationally designed small molecules is known to stabilize the native tetrameric state of TTR over the dissociative transition state, raising the kinetic barrier, imposing kinetic stabilization on the tetramer and preventing amyloidogenesis (<a href="#R3" class="usa-link" aria-describedby="R3">3</a>, <a href="#R16" class="usa-link" aria-describedby="R16">16</a>, <a href="#R18" class="usa-link" aria-describedby="R18">18</a>).</p>
<p id="P5">Previous studies have focused on rational ligand design and as a result most of the TTR stabilizers reported to date are halogenated biaryl analogues of T<sub>4</sub>, many resembling non-steroidal anti-inflammatory drugs (NSAIDs). Some of these compounds, such as the NSAID diflunisal, which is currently tested in clinical trials in FAP patients for its efficacy to ameliorate peripheral neuropathy resulting from TTR deposition, (<a href="#R19" class="usa-link" aria-describedby="R19">19</a>) have anti-inflammatory activity (<a href="#R20" class="usa-link" aria-describedby="R20">20</a>, <a href="#R21" class="usa-link" aria-describedby="R21">21</a>). The pharmacological effects of NSAIDs are due to inhibition of cyclo-oxygenase (COX) enzymes (<a href="#R22" class="usa-link" aria-describedby="R22">22</a>). Inhibition of COX-1 can produce side effects such as gastrointestinal irritation, leading to ulcers and bleeding (<a href="#R23" class="usa-link" aria-describedby="R23">23</a>). Inhibition of COX-2 has been associated with an increased risk of severe cardiovascular events, including heart failure, particularly in patients with preexisting cardiorenal dysfunction (<a href="#R20" class="usa-link" aria-describedby="R20">20</a>, <a href="#R21" class="usa-link" aria-describedby="R21">21</a>, <a href="#R24" class="usa-link" aria-describedby="R24">24</a>, <a href="#R25" class="usa-link" aria-describedby="R25">25</a>). Therefore, heart and kidney impairment are exclusion criteria for participation of patients in the diflunisal clinical trials to treat TTR-mediated FAP (<a href="#R19" class="usa-link" aria-describedby="R19">19</a>). Genomic variations can increase the sensitivity of individuals to adverse side effects of NSAIDs. Serum concentrations of NSAIDs depend on CYP2C9 and/or CYP2C8 activity. <em>CYP2C9</em> polymorphism might play a significant role in the profile of adverse side effects of NSAID and alleles that affect the activity of <em>CYP2C9</em> are found at different frequency in subjects of Caucasian, African or Asian descent (<a href="#R26" class="usa-link" aria-describedby="R26">26</a>, <a href="#R27" class="usa-link" aria-describedby="R27">27</a>). Hence, the long-term therapy with drugs that have inhibitory effect on COX activity to prevent TTR aggregation is especially problematic in patients who suffer from TTR-mediated cardiomyopathy. The design and development of drugs to treat/prevent FAC or SSA thus presents the challenge not only to find compounds with a greater variety of chemical scaffolds that accomplish stabilization, but do so without the adverse side effects due to inhibition of COX activity.</p>
<p id="P6">For these reasons, the development of a rapid and robust screen for compounds that bind to and stabilize TTR could be useful. To date, no high-throughput screening (HTS) methodology is available for the discovery of TTR ligands (<a href="#R28" class="usa-link" aria-describedby="R28">28</a>,<a href="#R29" class="usa-link" aria-describedby="R29">29</a>). Therefore, we developed a versatile fluorescence polarization (FP) based HTS assay that can detect binding of small molecules to the T<sub>4</sub> binding pocket of TTR under physiological conditions.</p></section><section id="S2"><h2 class="pmc_sec_title">RESULTS</h2>
<section id="S3"><h3 class="pmc_sec_title">Design and synthesis of the TTR FP probe</h3>
<p id="P7">FP is used to study molecular interactions by monitoring changes in the apparent size of a fluorescently labeled molecule. Binding is measured by an increase in the FP signal, which is proportional to the decrease in the rate of tumbling of a fluorescent ligand upon association with macromolecules such as proteins (<a href="#F1" class="usa-link">Fig. 1A</a>). To synthesize a fluorescent TTR ligand <strong>1</strong>, we initially started with the NSAID diflunisal analogue <strong>2</strong> (<a href="#F1" class="usa-link">Fig. 1B</a>) (<a href="#R30" class="usa-link" aria-describedby="R30">30</a>). The product of attaching a linker to <strong>2</strong>, compound <strong>3</strong>, had very low binding affinity to TTR (<em>K</em><sub>d1</sub> &gt; 3290 nM, <a href="#SD1" class="usa-link">fig. S1A</a> and <a href="#SD1" class="usa-link">fig. S1B</a>). The crystal structure of the diclofenac analog <strong>4</strong> showed that the phenolic hydroxyl flanked by the two chlorine atoms is oriented out of the binding pocket into the solvent (<a href="#R31" class="usa-link" aria-describedby="R31">31</a>). We reasoned that attaching a PEG amine linker to the phenol group of <strong>4</strong> would generate compound <strong>5</strong> which would bind to TTR (<a href="#F1" class="usa-link">Fig. 1B</a> and <a href="#SD1" class="usa-link">fig. S1C</a>). <strong>5</strong> was coupled to fluorescein isothiocyanate (FITC) to produce the FITC-coupled TTR FP probe (<strong>1</strong>, <a href="#F1" class="usa-link">Fig. 1B</a>). The binding characteristics of the probe (<em>K</em><sub>d1</sub> = 13 nM and <em>K</em><sub>d2</sub> = 100 nM) were assessed with ITC (<a href="#F2" class="usa-link">Fig. 2A</a>).</p>
<figure class="fig xbox font-sm" id="F1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3227540_nihms337580f1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a4/3227540/defcdb2dee20/nihms337580f1.jpg" loading="lazy" height="823" width="538" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/F1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Schematic of the FP assay and structures of TTR ligands and FP probe <strong>1</strong>. (<strong>A)</strong> The rate of tumbling of fluorescent probe <strong>1</strong> decreases upon binding to TTR, which results in increasing its fluorescence polarization signal. (<strong>B</strong>) Chemical structures of the TTR ligands <strong>2–5</strong> used to design probe <strong>1</strong>.</p></figcaption></figure><figure class="fig xbox font-sm" id="F2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3227540_nihms337580f2.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a4/3227540/b79fc54d2c6d/nihms337580f2.jpg" loading="lazy" height="939" width="755" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/F2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Assessment of FP probe <strong>1</strong> binding to TTR and structures of TTR ligands. <strong>(A</strong>) Assessment of the binding affinity of probe <strong>1</strong> to TTR by ITC. Calorimetric titration of probe <strong>1</strong> against TTR (<em>K</em><sub>d,1</sub> = 13 nM and <em>K</em><sub>d,2</sub> = 100 nM). Raw data (top) and integrated heats (bottom) from the titration of TTR (2 μM) with probe (25 μM). The solid red line represents the best fit binding isotherm to a two-site binding model. (<strong>B</strong>) FP saturation binding between probe <strong>1</strong> (0.1 μM) and increasing concentration of TTR (0.005 to 10 μM) (<strong>C</strong>) Competition of probe <strong>1</strong> from TTR by increasing concentrations (0.01 μM – 50 μM) of ligand <strong>2 (</strong><em>K</em>app = 0.231 μM, <em>R</em><sup>2</sup> = 0.997). FP Assays were performed in triplicate. Error bars: SD. (<strong>D</strong>) Structures of the newly identified TTR ligands. Compounds with co-crystal structures in <a href="#F5" class="usa-link">Fig. 5</a> are labeled in red in all figures.</p></figcaption></figure></section><section id="S4"><h3 class="pmc_sec_title">Evaluation of the FP assay</h3>
<p id="P8">The binding of <strong>1</strong> to TTR was evaluated to test its suitability for the FP assay with a standard saturation binding experiment. A fixed concentration of probe <strong>1</strong> (0.1 μM) was incubated with increasing concentrations of TTR (0.005 μM to 10 μM) and the formation of <strong>1</strong>•TTR complex was quantified by the increase in FP signal (excitation λ 485 nm, emission λ 525 nm) relative to the concentration of TTR (<a href="#F2" class="usa-link">Fig. 2B</a>). The fluorescence polarization increased with the concentration of TTR until saturation was reached. A large dynamic range (70 – 330 mP) was measured for the assay. To validate the FP assay, we tested known TTR binders in a displacement assay (for detailed information see <a href="#SD1" class="usa-link">Supplemental Material</a>). Compound <strong>2</strong> (<em>K</em><sub>app</sub> = 231 nM, <em>R</em><sup>2</sup> = 0.997), Thyroxine (T<sub>4</sub>) (<em>K</em><sub>app</sub> = 186 nM, <em>R</em><sup>2</sup> = 0.998) and diclofenac (<em>K</em><sub>app</sub> = 4660 nM, <em>R</em><sup>2</sup> = 0.999) decreased the FP signal in a dose-dependent manner (<a href="#F2" class="usa-link">Fig. 2C</a>, <a href="#SD1" class="usa-link">fig. S2B and S2C</a>). The FP assay is a competitive displacement assay and therefore it provides apparent binding constants (<em>K</em><sub>app</sub>). However, these apparent binding constants correlate well with the data obtained by ITC which measures direct interactions in solution and gives an actual (<em>K</em><sub>d</sub>) value (<a href="#SD1" class="usa-link">table S1</a>).</p></section><section id="S5"><h3 class="pmc_sec_title">Adaptation of the FP assay for HTS</h3>
<p id="P9">Next, we optimized the FP assay for HTS and screened a ~130,000 small molecule library for compounds that displaced probe <strong>1</strong> from the T<sub>4</sub> binding sites of TTR. The FP assay was performed in 384-well plates with low concentrations of probe <strong>1</strong> (1.5 nM) and TTR (50 nM) in a 10 μL assay volume. Detergent (0.01% Triton X-100) was added to the assay buffer to avoid false positive hits from aggregation of the small molecules. The assay demonstrated robust performance, with a, large dynamic range (~70–230 mP) and a Z′ factor (<a href="#R32" class="usa-link" aria-describedby="R32">32</a>, <a href="#R33" class="usa-link" aria-describedby="R33">33</a>) in the range of 0.57–0.78 (<a href="#SD1" class="usa-link">fig. S3A and S3B</a>).</p>
<p id="P10">Hits were defined as compounds, which resulted in at least 50% decrease in FP and demonstrated relative fluorescence between 70 and 130%. Many fluorescence quenchers and enhancers, which have less than 70% and greater than 130% total fluorescence relative to a control (compound without TTR), were excluded from the hit list. The excluded compounds have native fluorescence that is similar to fluorescein, which would interfere with the FP measurements and result in false positive hits. Two hundred compounds were designated as positive hits (0.167% hit rate). The top 33 compounds (compounds with lowest FP IC<sub>50</sub>) were assayed in a 10-point duplicate dose-response FP assay and displayed an IC<sub>50</sub> (concentration that resulted in 50% decrease in the FP signal) between 0.277 and 10.957 μM (<a href="#SD1" class="usa-link">table S2</a>).</p></section><section id="S6"><h3 class="pmc_sec_title">Validation of the HTS hits</h3>
<p id="P11">The top 33 compounds were retested with the FP assay (<a href="#SD1" class="usa-link">table S2</a>) and with surface plasmon resonance (SPR) as another independent biophysical method. Solutions of the 33 hits were passed over immobilized, biotinylated TTR on a streptavidin coated chip. The binding of a small molecule to TTR on the sensor chip produces a SPR response signal (RU). The RU signal after addition of the top 33 compounds was measured and compared to a negative, solvent only, control. All compounds identified by the screen as hits were confirmed as TTR binders using SPR (<a href="#SD1" class="usa-link">fig. S4</a>). We also found known TTR binders, such as NSAIDs (diclofenac, meclofenamic acid, and niflumic acid) and isoflavones (apigenin) in our screen (<a href="#R3" class="usa-link" aria-describedby="R3">3</a>, <a href="#R34" class="usa-link" aria-describedby="R34">34</a>) (<a href="#SD1" class="usa-link">table S2</a>). Among the best ligands (<a href="#F2" class="usa-link">Fig. 2D</a>) were the NSAID, niflumic acid, two catechol-O-methyl-tranferase (COMT) inhibitors, 3,5-dintrocatechol and Ro 41-0960 (<a href="#R35" class="usa-link" aria-describedby="R35">35</a>) and a number of compounds not previously known to bind to TTR. The chemical structures of these ligands were confirmed by <sup>1</sup>H NMR and high-resolution mass spectrometry (HRMS) and the chemical purity was determined to be &gt;95% (<a href="#SD1" class="usa-link">fig. S5</a>).</p></section><section id="S7"><h3 class="pmc_sec_title">Inhibition of TTR amyloidogenesis by the HTS hits</h3>
<p id="P12">To test whether the new TTR ligands (7.2 μM) could function as kinetic stabilizers, we measured their ability to inhibit TTR (3.6 μM) amyloidogenesis at 72 hrs at pH 4.4 (<a href="#SD1" class="usa-link">fig. S6</a>) (<a href="#R29" class="usa-link" aria-describedby="R29">29</a>). All 33 compounds inhibited TTR aggregation (&lt;50% fibril formation, <a href="#SD1" class="usa-link">table S2</a>). Of these, 23 were very good (&lt;20% fibril formation) and 11 were excellent (&lt;2% fibril formation) TTR kinetic stabilizers (<a href="#F3" class="usa-link">Fig. 3A</a>). All of the potent TTR stabilizers, except niflumic acid, and the two COMT inhibitors 3,5-dintrocatechol and Ro 41-0960, were chemical entities with no previously reported biological activity. Since occupancy of only one T<sub>4</sub> binding site within TTR is sufficient for kinetic stabilization of the tetramer (<a href="#R3" class="usa-link" aria-describedby="R3">3</a>), we tested the most potent ligands at substoichiometric concentrations (2.4 fold molar excess of TTR relative to ligand) in a kinetic aggregation assay monitored over 5 days (<a href="#F3" class="usa-link">Fig. 3B</a>). Under these conditions ligands <strong>7</strong>, <strong>14</strong>, <strong>15</strong> and Ro 41-0960 dramatically slowed fibril formation and outperformed the known TTR stabilizer, diclofenac, which blocked only ~55% of TTR aggregation.</p>
<figure class="fig xbox font-sm" id="F3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3227540_nihms337580f3.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a4/3227540/9cf218ad0035/nihms337580f3.jpg" loading="lazy" height="1002" width="566" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/F3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Evaluation of inhibition of TTR aggregation and binding to THR and COX-1 (<strong>A</strong>) Percentage of TTR (3.6 μM) fibril formation in the presence of ligands (7.2 μM) relative to aggregation in the absence of ligands (denoted 100%) after 72 hours. (<strong>B</strong>) Comparison of TTR (3.6 μM) aggregation inhibition in the presence of substoichiometric amounts of ligands (3.0 μM) compared to diclofenac. (<strong>C</strong>) THR binding and COX-1 inhibition data for the most potent TTR ligands. THR binding is expressed as % displacement of <sup>125</sup>I-labeled triiodothyronine (T<sub>3</sub>) by test compounds (10 μM). COX-1 inhibition is shown as % inhibition of COX-1 mediated conversion by test compounds (10 μM). Error bars: SEM</p></figcaption></figure></section><section id="S8"><h3 class="pmc_sec_title">Evaluating the TTR ligands for COX-1 enzymatic inhibition and binding to thyroid hormone receptor</h3>
<p id="P13">A successful clinical candidate against TTR amyloid cardiomyopathy should have minimal off-target toxicity due to the potential need for life-long use of these drugs. Specifically, the TTR ligands should exhibit minimal binding to COX and the nuclear thyroid hormone receptor (THR). Inhibition of COX is contraindicated for treating FAC patients, since COX inhibition can not only lead to renal dysfunction and blood pressure elevation, but may precipitate heart failure in vulnerable individuals (<a href="#R20" class="usa-link" aria-describedby="R20">20</a>, <a href="#R21" class="usa-link" aria-describedby="R21">21</a>, <a href="#R24" class="usa-link" aria-describedby="R24">24</a>, <a href="#R25" class="usa-link" aria-describedby="R25">25</a>). Therefore, the most potent TTR ligands were evaluated for their ability to inhibit COX-1 activity, as well as, for binding to THR, in comparison with the NSAID niflumic acid. Although niflumic acid exhibited substantial (94%) COX-1 inhibition, three of the 12 new compounds evaluated (<strong>7, 6</strong> and <strong>10</strong>) displayed less than 1% inhibition of COX-1. Only one ligand (compound <strong>8</strong>) showed significant (58%) and two compounds (<a href="#R6" class="usa-link" aria-describedby="R6">6</a> and <a href="#R10" class="usa-link" aria-describedby="R10">10</a>) minor (5%) binding to THR (<a href="#F3" class="usa-link">Fig. 3C</a>).</p></section><section id="S9"><h3 class="pmc_sec_title">Characterization of the binding energetics to TTR</h3>
<p id="P14">Many reported TTR ligands, including T<sub>4</sub>, bind TTR with negative cooperativity, which appears to arise from subtle conformational changes in TTR upon ligand binding to the first T<sub>4</sub> site (<a href="#R3" class="usa-link" aria-describedby="R3">3</a>, <a href="#R16" class="usa-link" aria-describedby="R16">16</a>, <a href="#R36" class="usa-link" aria-describedby="R36">36</a>). We used ITC to determine the binding constants and to evaluate cooperativity between the two TTR T<sub>4</sub> sites (<a href="#F2" class="usa-link">Fig. 2A</a>, <a href="#F4" class="usa-link">Fig. 4A, Fig. 4B</a> and <a href="#SD1" class="usa-link">fig. S1</a> and <a href="#SD1" class="usa-link">fig. S7</a>). The ITC data for compounds <strong>1</strong>, <strong>7</strong>, <strong>14</strong>, and Ro 41-0906 binding to TTR were fit to a two-site binding model and show that these potent ligands bind TTR with low nanomolar affinity. The dissociation constants for these ligands indicated that they bound TTR with negative cooperativity (<a href="#SD1" class="usa-link">table S3</a>). Analysis of the free energies associated with ligand binding to TTR indicates that binding was driven both by burial of the hydrophobic ligand in the TTR binding site (which leads to the favorable binding entropies) and specific ligand-TTR interactions (which leads to the favorable binding enthalpies) (<a href="#F2" class="usa-link">Fig. 2A</a>, <a href="#F4" class="usa-link">Fig. 4A, Fig. 4B</a>, and <a href="#SD1" class="usa-link">fig. S7B</a>) (<a href="#R37" class="usa-link" aria-describedby="R37">37</a>). The binding of compounds <strong>7</strong> (<em>K</em><sub>d1</sub> = 58 nM and <em>K</em><sub>d2</sub> = 500 nM) and <strong>14</strong> (<em>K</em><sub>d1</sub> = 26 nM and <em>K</em><sub>d2</sub> = 1800 nM) to TTR did not cause major conformational changes to the TTR tetramer structure (<a href="#F5" class="usa-link">Fig. 5</a>).</p>
<figure class="fig xbox font-sm" id="F4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3227540_nihms337580f4.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a4/3227540/425f362337be/nihms337580f4.jpg" loading="lazy" height="603" width="526" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/F4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Assessment of the binding of ligands Ro 41-0960 and 7 to TTR using ITC and SPR. Calorimetric titration of (<strong>A</strong>) Ro 41-0960 (K<sub>d,1</sub> = 15 nM and K<sub>d,2</sub> = 2000 nM) and <strong>(B</strong>) <strong>7</strong> (K<sub>d,1</sub> = 58 nM and K<sub>d,2</sub> = 500 nM) against TTR. Raw data (top) and integrated heats (bottom) from the titration of TTR (2 μM) with ligand (25 μM). The solid red line through the integrated heats represents the best fit binding isotherm to a two-site binding model. (<strong>C</strong>) SPR sensogram showing concentration-dependent binding of ligand <strong>7</strong> to TTR (0.001 μM to 2.2 μM). Normalized RUs are plotted over a time course. Equilibrium binding analysis (inset) indicates an apparent <em>K</em>d of 57.91 ± 13.2 nM (SD).</p></figcaption></figure><figure class="fig xbox font-sm" id="F5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3227540_nihms337580f5.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a4/3227540/9423927a039b/nihms337580f5.jpg" loading="lazy" height="566" width="766" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/F5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Crystal structures of WT-TTR bound to <strong>T4</strong>, <strong>Ro 41-0960</strong>, <strong>14, 7</strong>, and <strong>9</strong> (<strong>A</strong>) Ribbon diagram of WT-TTR with T<sub>4</sub> bound to each of the two T<sub>4</sub> binding pockets within the tetramer (monomer subunits individually colored). (<strong>B</strong>) Expanded view of T<sub>4</sub> within the binding site with a “Connelly” analytical molecular surface applied to residues within 8 Å of ligand (green = hydrophobic, purple = polar). (<strong>C</strong> to <strong>F</strong>) Expanded views of Ro 41-0960, <strong>14</strong>, <strong>7</strong>, and <strong>9</strong> bound to TTR. Hydrogen bonds are represented as dashed lines between functional groups. The innermost halogen binding pockets (HBPs) 3 and 3′ are composed of the methyl and methylene groups of Ser117/117′, Thr119/119′, and Leu110/110′. HBPs 2 and 2′ are assembled from the side chains of Leu110/110′, Ala109/109′, Lys15/15′, and Leu17/17′. The outermost HBPs 1 and 1′ (labeled in <strong>a</strong>) are lined by the methyl and methylene groups of Lys15/15′, Ala108/108′, and Thr106/106 ′ (Thr 106 not shown).</p></figcaption></figure><p id="P15">We explored the binding kinetics of the potent TTR ligands <strong>7</strong> and Ro 41-0960 by SPR (<a href="#F4" class="usa-link">Fig. 4C</a> and <a href="#SD1" class="usa-link">fig. S4B</a>). Ligand <strong>7</strong> exhibited concentration-dependent binding to TTR with a K<sub>d</sub> of 57.91± 13.2 nM, determined by fitting steady state data (<a href="#F4" class="usa-link">Fig. 4C</a>) (<a href="#R38" class="usa-link" aria-describedby="R38">38</a>). This affinity was similar to the one obtained by ITC (K<sub>d,1</sub> = 58 nM). Measurement of the binding kinetics of ligand <strong>7</strong> to TTR gave a similar binding constant (K<sub>d</sub> = 20.22 ± 2.04 nM) to the one determined from the steady state data. Target residence time (τ), the reciprocal of k<sub>off</sub>, differentiates between transient and long-lived ligand-protein complexes. Compounds that dissociate from their target slowly have a longer τ, allowing less frequent administration. Ligand <strong>7</strong> had favorable binding kinetics to TTR with rapid on-rate and a slow off-rate (longer τ) (k<sub>on</sub> = 1.29 × 10<sup>6</sup> ± 1.3 × 10<sup>5</sup> M<sup>−1</sup>s<sup>−1</sup> and k<sub>off</sub> = 0.026 ± 0.001 s<sup>−1</sup>). Ro 41-0960 also showed similar binding kinetics as ligand <strong>7</strong> (K<sub>d</sub> = 56.05 ± 4.14 nM, k<sub>on</sub> = 2.35 × 10<sup>6</sup> ± 1.5 × 10<sup>5</sup> M<sup>−1</sup>s<sup>−1</sup> and k<sub>off</sub> = 0.132 ± 0.009 s<sup>−1</sup>), although the k<sub>off</sub> was ~5x faster (<a href="#SD1" class="usa-link">fig. S4B</a>). In contrast, NSAIDs such as niflumic acid and diclofenac displayed a much faster dissociation from TTR (k<sub>off</sub> = 0.523 s<sup>−1</sup> and 1.01 s<sup>−1</sup>, respectively) compared to ligand <strong>7</strong> or Ro 41-0960 (~ 20x or 40x lower target residence time than ligand <strong>7</strong>) (<a href="#SD1" class="usa-link">fig. S4C</a> and <a href="#SD1" class="usa-link">fig. S4D</a>).</p></section><section id="S10"><h3 class="pmc_sec_title">Crystal structures of WT • Ligand complexes</h3>
<p id="P16">The crystal structures of WT-TTR in complex with Ro 41-0960, <strong>7</strong>, <strong>9</strong> and <strong>14</strong> were determined to 1.25, 1.45, 1.50 and 1.60-Å resolutions, respectively (<a href="#F5" class="usa-link">Fig. 5</a>). Known TTR kinetic stabilizers are composed of two substituted aryl rings connected by a linker (<a href="#R39" class="usa-link" aria-describedby="R39">39</a>), but the FP-based HTS screen identified molecules with distinct ring systems (<a href="#F2" class="usa-link">Fig. 2D</a>). The 2-imino-1-methylimidazolidin-4-one ring of <strong>14,</strong> the 3,5-dimethyl-1<em>H</em>-pyrazole ring of <strong>7,</strong> and the pyridine ring of <strong>9,</strong> all sat within the inner cavity of the T<sub>4</sub> binding site, and were able to hydrogen bond with the Ser117 and Thr109 that comprise the innermost boundary of the T<sub>4</sub> binding site (<a href="#F5" class="usa-link">Fig. 5C–F</a>). The 3,5-methyl groups of <strong>7</strong> extended into the two symmetrical HBPs, 3 and 3′. In doing so, the two amino nitrogens of the pyrazole ring formed hydrogen bonds with Ser117 and 117′ similar to the single H-bond made by the pyridine ring of <strong>9</strong>, while the 2-imino-1-methylimidazolidin-4-one ring of <strong>14</strong> formed the most extensive, hydrogen-bond network with Thr109 and 109′ and Ser117 and 117. ′ The aforementioned hydrogen-bonds tethered these ring systems in position (<a href="#F5" class="usa-link">Fig. 5C–F</a>). Although it has been reported that hydrophobic linkers are preferred for ligand binding within HBP2 and 2′, the compounds identified here had diverse linkers that enable the adjoined rings to have sufficient flexibility to make optimal interactions with HBPs 1,1′ and 3,3′ (<a href="#R39" class="usa-link" aria-describedby="R39">39</a>). The 2-fluoro substituted phenyl ring of <strong>7</strong> and the ethoxy benzyl ring of <strong>9</strong> occupied the outer binding cavity, placing a portion of the aryl ring into HBP1 or 1′. The 3,4-dihydroxy-5-nitrophenyl and 3,5-dibromo-phenyl rings of Ro 41-0960 and <strong>14</strong>, respectively, displayed an acidic phenol, which was able to make electrostatic interactions with Lys15 and 15′ through a putative phenolate -LysNH<sub>3</sub><sup>+</sup> bridge (<a href="#R30" class="usa-link" aria-describedby="R30">30</a>). This interaction closed the T<sub>4</sub> pocket around the inhibitor (<a href="#F5" class="usa-link">Fig. 5C and 5D</a>).</p>
<p id="P17">This combination of the electrostatic and hydrophobic interactions bridged and stabilized the two adjacent TTR subunits across the weaker TTR dimer–dimer interface, resulting in native state stabilization (<a href="#R3" class="usa-link" aria-describedby="R3">3</a>), which subsequently increased the activation energy for tetramer dissociation, the rate-limiting step in TTR amyloidogenesis cascade (<a href="#R3" class="usa-link" aria-describedby="R3">3</a>, <a href="#R17" class="usa-link" aria-describedby="R17">17</a>, <a href="#R18" class="usa-link" aria-describedby="R18">18</a>). The structural analysis of WT-TTR in complex with <strong>14</strong> (<a href="#F5" class="usa-link">Fig. 5D</a>) suggested why this compound was a very strong TTR kinetic stabilizer, as it made multiple hydrogen bonds with TTR within the T<sub>4</sub> binding site, while engaging in electrostatic interactions with Lys15 and Lys15′ at the periphery of the pocket.</p></section><section id="S11"><h3 class="pmc_sec_title">Kinetic stabilizers prevent TTR-induced cytotoxicity against human cardiac and neuronal cell lines</h3>
<p id="P18">Because, there are no mouse models of V122I-TTR FAC, we turned to a recently developed in vitro cell-based assay, which employs the human cardiac cell line AC16 (<a href="#R40" class="usa-link" aria-describedby="R40">40</a>). The AC16 cell line was generated from adult ventricular cardiomyocytes (<a href="#R41" class="usa-link" aria-describedby="R41">41</a>), which is one of the sites of TTR amyloid deposition. This cellular model is currently the patho-physiologically most relevant tissue culture model for SSA and FAC. Treatment of AC16 cells with the destabilized V122I TTR variant decreased cell viability to 49±1% relative to vehicle treated cells (100% viability). Most of the ligands identified by our HTS effectively prevented the proteotoxicity of V122I TTR towards AC16 cells (<a href="#F6" class="usa-link">Fig. 6A</a>). We also assessed the toxicity of WT-TTR towards human neuroblastoma cell line IMR-32, as an in vitro a model for FAP (<a href="#R42" class="usa-link" aria-describedby="R42">42</a>), which provided similar results (<a href="#SD1" class="usa-link">fig. S8B</a>). Ro 41-0960 and ligands <strong>7</strong>, <strong>14</strong> and <strong>15</strong> completely rescued AC16 cell viability (<a href="#F6" class="usa-link">Fig. 6A</a>). None of the compounds identified in the HTS were cytotoxic to AC16 cells or to IMR-32 cells at the concentration tested (<a href="#SD1" class="usa-link">fig. S8A</a> and <a href="#SD1" class="usa-link">fig. S8C</a>). Unexpectedly, despite their potency as TTR stabilizers and lack of cellular toxicity (<a href="#F3" class="usa-link">Fig. 3A</a> and <a href="#SD1" class="usa-link">fig. S8A</a> and <a href="#SD1" class="usa-link">fig. S8C</a>), the COMT inhibitor, 3,5-dinitrocatechol, and the NSAID, niflumic acid, performed poorly in the cell culture system (<a href="#F6" class="usa-link">Fig. 6A</a> and <a href="#SD1" class="usa-link">fig. S8B</a>).</p>
<figure class="fig xbox font-sm" id="F6"><h4 class="obj_head">Fig. 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3227540_nihms337580f6.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a4/3227540/05a976588499/nihms337580f6.jpg" loading="lazy" height="562" width="767" alt="Fig. 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/F6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Inhibition of V1221I TTR cytotoxicity and stabilization of human serum TTR. (<strong>A</strong>) Inhibition of V1221I TTR cytotoxicity towards AC16 cells. TTR and ligands concentration: 8 μM. Resveratrol is a positive control. Cell viability is shown relative to cells treated with vehicle only. Error bars: SEM (<strong>B</strong>) Quantitative analysis of TTR serum stability after 72 hours. (<strong>C</strong>&amp;<strong>D</strong>) Stabilization of human serum TTR. Serum TTR in the presence and absence 50 μM compounds was subjected to acid denaturation. TTR immunoblot at 0 <strong>(C)</strong> and 72 (<strong>D</strong>) hours after acidification of serum</p></figcaption></figure></section><section id="S12"><h3 class="pmc_sec_title">Stabilization of serum TTR against acid-mediated dissociation and amyloidogenesis</h3>
<p id="P19">To stabilize the TTR tetramer and thus prevent amyloid fibril formation in FAC or SSA, small molecules must be able to selectively bind to TTR in human serum over other serum proteins. Compounds that bind to TTR selectively in serum are the best candidates for further evaluation. The 12 most potent ligands, identified in this HTS, were tested for their ability to stabilize TTR in human serum (<a href="#F6" class="usa-link">Fig. 6B–D</a>). Since TTR must first dissociate into monomers in order to denature and aggregate, we tested how much intact TTR tetramer remained after 72 hours of acid treatment in the presence and absence of 50 μM TTR ligands (TTR concentration in human serum is ~ 3–5 μM). We compared our TTR ligands to diflunisal, which had previously been shown to inhibit acid-mediated tetramer dissociation and aggregation of serum wild type and FAP-mutant TTR (<a href="#R43" class="usa-link" aria-describedby="R43">43</a>). Seven of the twelve newly identified TTR ligands almost fully stabilized serum TTR (% tetramer at 72 hours: 75.5 - 100% of tetramer present at 0 hours) at 50 μM (<a href="#F6" class="usa-link">Fig. 6B–D</a>). At 50 μM, diflunisal (%tetramer at 72hrs: 17.5%) and niflumic acid (%tetramer at 72hrs: 11.5%), as well as 3,5-dinitrocatechol (%tetramer at 72hrs: 37.6%), compound 10 (%tetramer at 72hrs: 43.6%) and compound 12 (%tetramer at 72hrs: 24.3%), were unable to completely stabilize TTR. At 200 μM, which is within the therapeutic concentration range of diflunisal (100–200 μM), all tested compounds stabilized TTR (<a href="#SD1" class="usa-link">fig. S9</a>).</p></section></section><section id="S13"><h2 class="pmc_sec_title">DISCUSSION</h2>
<p id="P20">Amyloidosis is a systemic disease caused by structural alteration of proteins that tend to precipitate in the extracellular space as insoluble fibrils. FAC is a hereditary TTR-related systemic amyloidosis with predominant cardiac involvement resulting from myocardial infiltration of amyloid protein. There are currently no FDA-approved drugs for prevention or treatment of TTR-induced amyloid cardiomyopathy and the therapy for most patients is confined to symptomatic relief. Liver transplantation, which removes the source of the pathologic protein, has been the treatment of choice for hereditary TTR amyloidoses. Heart transplantation is performed as a palliative measure for a subset of FAC patients who display predominately cardiac pathology and only mild systemic involvement (<a href="#R44" class="usa-link" aria-describedby="R44">44</a>,<a href="#R45" class="usa-link" aria-describedby="R45">45</a>).</p>
<p id="P21">Small molecules targeting the formation, clearance, or assembly of toxic aggregates provide a promising strategy to treat amyloidoses (<a href="#R3" class="usa-link" aria-describedby="R3">3</a>, <a href="#R16" class="usa-link" aria-describedby="R16">16</a>, <a href="#R46" class="usa-link" aria-describedby="R46">46</a>). A number of disease causing mutations (e.g., L55P, V30M, and V122I) influence the thermodynamic stability and the kinetics of dissociation of the TTR tetramer in vitro, and these properties of the variant tetramers appear to be correlated to the severity of the resulting disease (<a href="#R47" class="usa-link" aria-describedby="R47">47</a>,<a href="#R48" class="usa-link" aria-describedby="R48">48</a>). Moreover, suppressor mutations in TTR (e.g., T119M) that kinetically stabilize the native tetramer and protect against the development of pathology in compound heterozygotes carrying a disease-associated mutation, have been identified (<a href="#R49" class="usa-link" aria-describedby="R49">49</a>).</p>
<p id="P22">Binding of small molecule ligands to the unoccupied thyroxine (T<sub>4</sub>) binding sites of TTR stabilizes the TTR tetramer and slows tetramer dissociation and amyloidogenesis in vitro. These kinetic stabilizers could potentially be used as small molecule therapeutics for the treatment of TTR amyloidoses (for review see: (<a href="#R16" class="usa-link" aria-describedby="R16">16</a>, <a href="#R46" class="usa-link" aria-describedby="R46">46</a>,<a href="#R50" class="usa-link" aria-describedby="R50">50</a>).</p>
<p id="P23">Recently clinical trials of TTR kinetic stabilizers have been initiated in FAP patients. The two compounds, which are being tested are the NSAID, diflunisal (<a href="#R19" class="usa-link" aria-describedby="R19">19</a>), and the benzoxazole, tafamidis (<a href="#R51" class="usa-link" aria-describedby="R51">51</a>). Due to the lack of animal models that faithfully reproduce the pathology of human TTR-mediated familial amyloidoses, the efficacy of TTR kinetic stabilizers was assessed in human FAP patients. Several transgenic mouse models that overexpress human mutant TTR (V30M) do not reproduce the tissue distribution of TTR deposits observed in peripheral nerves of human FAP patients carrying the same mutation (<a href="#R52" class="usa-link" aria-describedby="R52">52</a>,<a href="#R53" class="usa-link" aria-describedby="R53">53</a>). No mouse models that express transgenic human V122I TTR have been generated. In addition, the level of TTR overexpression required to observe TTR amyloid deposits in mice is very high. Because of the stoichiometric requirements of small molecule to TTR tetramer the concentrations of drug required to stabilize transgenic human TTR are difficult to achieve in these mouse models (<a href="#R2" class="usa-link" aria-describedby="R2">2</a>,<a href="#R3" class="usa-link" aria-describedby="R3">3</a>). Almost all existing TTR kinetic stabilizers were identified by structure-based drug designs and time consuming assays, performed under non-physiological binding conditions. One such assay uses the displacement of radioactively-labeled T<sub>4</sub> from TTR (<a href="#R28" class="usa-link" aria-describedby="R28">28</a>). However, the use of radioactivity makes it unsuitable for HTS. Another assay is based on the ability of TTR binders to stabilize TTR during acid-mediated aggregation (<a href="#R29" class="usa-link" aria-describedby="R29">29</a>). This is a simple but cumbersome assay (72 hours), which requires long incubation times, large amounts of protein and little kinetic information about ligand binding. In contrast, the FP-based assay we developed provided a simple, sensitive, and robust method that detected the binding of small molecules to the T<sub>4</sub> binding pocket of TTR under physiological conditions.</p>
<p id="P24">Preliminary results indicate that probe <strong>1</strong> bound to TTR in human serum (<a href="#SD1" class="usa-link">fig. S10</a>). The measurement of TTR concentrations in blood samples is clinically used as a sensitive indicator of the nutritional status of patients. The half-life of TTR in humans <em>in vivo</em> is about 2–4 days, which is much shorter than that of other nutritional markers such as albumin (approximately 20 days). Therefore, TTR concentration is more sensitive to changes in protein-energy status than albumin as it reflects recent dietary intake rather than overall nutritional status. In addition to being an excellent small molecule screening tool, this new FP assay has the potential to be developed as an alternative to the more error-prone immunoprecipitation-turbidity assay that is used by many clinical laboratories to determine plasma TTR concentrations (<a href="#R54" class="usa-link" aria-describedby="R54">54</a>).</p>
<p id="P25">The FP assay was adapted for HTS and enabled us to identify a variety of highly potent and structurally diverse TTR kinetic stabilizers. Most TTR ligands up to date were identified by rational design. Consequently their chemical diversity is limited and many have COX-inhibitory activity. Genomic variations in the human population are known to influence the response to pharmacotherapy. Hence, in the current era of pharmacogenomics it seems desirable not to limit disease therapy to a “one drug fits all” system. Unlike many previously reported halogenated TTR ligands, most of the new chemical TTR binding scaffolds we discovered using this HTS, had minimal COX-1 or THR activity. Many of the known kinetic stabilizers of TTR, including diflunisal, which has been in clinical trials for FAP since 2006 (<a href="#R19" class="usa-link" aria-describedby="R19">19</a>), show inhibitory activity towards COX. While there is never a simple way to predict whether a compound will be effective in all patients or whether individuals will suffer from adverse side effects, it is well known that COX inhibitors are associated with a number of adverse side effects, especially in patients with already compromised cardiac function, which makes their use in patients suffering from cardiomyopathy problematic. These adverse reactions include renal dysfunction and elevated blood pressure and they may precipitate heart failure in vulnerable individuals (<a href="#R20" class="usa-link" aria-describedby="R20">20</a>, <a href="#R21" class="usa-link" aria-describedby="R21">21</a>, <a href="#R24" class="usa-link" aria-describedby="R24">24</a>, <a href="#R25" class="usa-link" aria-describedby="R25">25</a>, <a href="#R55" class="usa-link" aria-describedby="R55">55</a>).</p>
<p id="P26">Our newly identified TTR kinetic stabilizers were able to rescue cardiomyocytes from the proteotoxicity of TTR aggregates thought to cause FAC and SSA in patients. Thus these compounds offer additional classes of highly effective TTR tetramer stabilizers. Several of the new TTR ligands we identified appeared to be very selective for TTR in human serum, where they stabilized human TTR even in the presence of all other serum proteins such as albumin. Eight of the twelve ligands we tested were more potent TTR stabilizers (at 50 μM) than diflunisal, which is currently in clinical trials for the treatment of FAP. Binding to serum proteins is an important factor in determining the overall distribution, metabolism, activity, and toxicity of a drug. When ligands exhibit excellent TTR amyloid fibril inhibition data in vitro, yet display poor serum selectivity, it is assumed that they prefer to bind to the drug-binding sites in albumin and/or similar sites in other proteins found in plasma. It is unlikely that such promiscuous inhibitors will prevent TTR misfolding and amyloidosis in a complex environment like human blood or CSF.</p>
<p id="P27">The ligands we identified should be effective against SSA and FAC, because they bound both WT and V122I mutant TTR to kinetically stabilize tetramers. In conclusion, we discovered a number of new chemical scaffolds that were able to stabilize wt and mutant TTR and our data provide the incentive to further evaluate the efficacy of the most selective and potent ligands against FAC and SSA. No FDA-approved drugs or accepted therapeutic strategies are at this time available for treating SSA and FAC. Hence, we envision that several of the new TTR kinetic stabilizers described in this manuscript might be promising leads to be developed as therapeutics for FAC and SSA.</p></section><section id="S14"><h2 class="pmc_sec_title">Supplementary Material</h2>
<section class="sm xbox font-sm" id="SD1"><div class="caption p">
<span>Supplemental Information</span><p id="P28">Fig. S1. Calorimetric titration of ligands against TTR.</p>
<p id="P29">Fig. S2. Displacement FP assay of TTR ligands.</p>
<p id="P30">Fig. S3. Dynamic range and Z′ factor for the FP assay.</p>
<p id="P31">Fig. S4. Confirmation and assessment of ligands binding to TTR using SPR.</p>
<p id="P32">Fig. S5. <sup>1</sup>H NMR (chemical shifts and spectra), HRMS, and HPLC traces for HTS hits.</p>
<p id="P33">Fig. S6. Cartoon of TTR fibril formation assay.</p>
<p id="P34">Fig. S7. Calorimetric titration of ligands against TTR.</p>
<p id="P35">Fig. S8. Cytotoxicity of TTR ligands (8 μM) towards AC16 cardiac cells and inhibition of WT-TTR cytotoxicity towards IMR-32 neuroblastoma cells by the TTR ligands.</p>
<p id="P36">Fig. S9. Stabilization of serum TTR against acid-mediated denaturation.</p>
<p id="P37">Fig. S10. Fluorescence polarization of probe binding to human serum TTR.</p>
<p id="P38">Fig. S11. Structure and crystal packing of TTR in complex with <strong>14</strong>.</p>
<p id="P39">Table S1. Affinity of ligands as determined by ITC and FP.</p>
<p id="P40">Table S2. Chemical structures of TTR ligands. <sup>a</sup>TTR amyloidogenesis inhibition activity (%fibril formation). <sup>b</sup>IC<sub>50</sub> (compound concentration that resulted in 50% decrease in the FP signal).</p>
<p id="P41">Table S3. Isothermal Titration Calorimetry (ITC) analysis of ligands binding to human wild type TTR.</p>
<p id="P42">Table S4. X-ray data collection and refinement statistics.</p>
<p id="P43">Table S5. Summary of small molecule screening data.</p>
<p id="P44">Tables S6. Information summary about TTR FP Probe <strong>1</strong>.</p>
</div>
<div class="media p" id="N0x193fa200N0x1a353600"><div class="caption">
<a href="/articles/instance/3227540/bin/NIHMS337580-supplement-Supplemental_Information.pdf" data-ga-action="click_feat_suppl" class="usa-link">NIHMS337580-supplement-Supplemental_Information.pdf</a><sup> (4.6MB, pdf) </sup>
</div></div></section></section><section id="S15" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>We thank; D. Solow-Cordero for help with the HTS, G. Crabtree for critical reading of the manuscript, C. Garcia for use of the Biacore T100, Alexandra Esteras-Chopo for advice and M. Davidson for providing the AC16 cell line.</p>
<p>Funding: This work was supported by the Hillblom Foundation (IAG), NIH Grants 5PN2EY016525 (IAG), DK 46335 (JWK), AI 42266 (IAW), by the Skaggs Institute of Chemical Biology (JWK, IAW).</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="FN3"><p>Author Contributions: M.M.A. designed and performed most experiments, S.C. performed crystallographic structure determination, A.C peformed the serum TTR stabilization. N.R. performed the cell-based assays. E.T.P. analyzed the ITC data. D.W.P. helped with probe synthesis. I.A.W. supervised the crystallographic work. J.W.K. supervised the work, S.C., N.R., I.A.W. and J.W.K. edited the paper. I.A.G supervised the work, M.M.A. and I.A.G prepared the manuscript.</p></div>
<div class="fn p" id="FN4"><p>Competing interests: The authors declare that they have no competing interests.</p></div>
<div class="fn p" id="FN5"><p>Accession codes: Atomic coordinates have been deposited in the RCSB Protein Data Bank and are available under accession codes 3P3R (Ro-41-0960), 3P3S (14), 3P3T (7) and 3P3U (9).</p></div>
</div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">REFERENCES AND NOTES</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="R1">
<span class="label">1.</span><cite>Selkoe DJ. Folding proteins in fatal ways. Nature. 2003;426:900–904. doi: 10.1038/nature02264.</cite> [<a href="https://doi.org/10.1038/nature02264" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14685251/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Folding%20proteins%20in%20fatal%20ways&amp;author=DJ%20Selkoe&amp;volume=426&amp;publication_year=2003&amp;pages=900-904&amp;pmid=14685251&amp;doi=10.1038/nature02264&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R2">
<span class="label">2.</span><cite>Cohen FE, Kelly JW. Therapeutic approaches to protein-misfolding diseases. Nature. 2003;426:905–909. doi: 10.1038/nature02265.</cite> [<a href="https://doi.org/10.1038/nature02265" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14685252/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Therapeutic%20approaches%20to%20protein-misfolding%20diseases&amp;author=FE%20Cohen&amp;author=JW%20Kelly&amp;volume=426&amp;publication_year=2003&amp;pages=905-909&amp;pmid=14685252&amp;doi=10.1038/nature02265&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R3">
<span class="label">3.</span><cite>Johnson SM, et al.  Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res. 2005;38:911–921. doi: 10.1021/ar020073i.</cite> [<a href="https://doi.org/10.1021/ar020073i" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16359163/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acc%20Chem%20Res&amp;title=Native%20state%20kinetic%20stabilization%20as%20a%20strategy%20to%20ameliorate%20protein%20misfolding%20diseases:%20a%20focus%20on%20the%20transthyretin%20amyloidoses&amp;author=SM%20Johnson&amp;volume=38&amp;publication_year=2005&amp;pages=911-921&amp;pmid=16359163&amp;doi=10.1021/ar020073i&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R4">
<span class="label">4.</span><cite>Monaco HL, Rizzi M, Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science. 1995;268:1039–1041. doi: 10.1126/science.7754382.</cite> [<a href="https://doi.org/10.1126/science.7754382" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7754382/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Structure%20of%20a%20complex%20of%20two%20plasma%20proteins:%20transthyretin%20and%20retinol-binding%20protein&amp;author=HL%20Monaco&amp;author=M%20Rizzi&amp;author=A%20Coda&amp;volume=268&amp;publication_year=1995&amp;pages=1039-1041&amp;pmid=7754382&amp;doi=10.1126/science.7754382&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R5">
<span class="label">5.</span><cite>Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898–909. doi: 10.1056/NEJM199709253371306.</cite> [<a href="https://doi.org/10.1056/NEJM199709253371306" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9302305/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=The%20systemic%20amyloidoses&amp;author=RH%20Falk&amp;author=RL%20Comenzo&amp;author=M%20Skinner&amp;volume=337&amp;publication_year=1997&amp;pages=898-909&amp;pmid=9302305&amp;doi=10.1056/NEJM199709253371306&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R6">
<span class="label">6.</span><cite>Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants. Amyloid. 2003;10:160–184. doi: 10.3109/13506120308998998.</cite> [<a href="https://doi.org/10.3109/13506120308998998" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14640030/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Tabulation%20of%20human%20transthyretin%20(TTR)%20variants&amp;author=LH%20Connors&amp;author=A%20Lim&amp;author=T%20Prokaeva&amp;author=VA%20Roskens&amp;author=CE%20Costello&amp;volume=10&amp;publication_year=2003&amp;pages=160-184&amp;pmid=14640030&amp;doi=10.3109/13506120308998998&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R7">
<span class="label">7.</span><cite>Jacobson DR, Gorevic PD, Buxbaum JN. A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology. Am J Hum Genet. 1990;47:127–136.</cite> [<a href="/articles/PMC1683748/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2349941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Hum%20Genet&amp;title=A%20homozygous%20transthyretin%20variant%20associated%20with%20senile%20systemic%20amyloidosis:%20evidence%20for%20a%20late-onset%20disease%20of%20genetic%20etiology&amp;author=DR%20Jacobson&amp;author=PD%20Gorevic&amp;author=JN%20Buxbaum&amp;volume=47&amp;publication_year=1990&amp;pages=127-136&amp;pmid=2349941&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R8">
<span class="label">8.</span><cite>Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006;166:1805–1813. doi: 10.1001/archinte.166.17.1805.</cite> [<a href="https://doi.org/10.1001/archinte.166.17.1805" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17000935/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Intern%20Med&amp;title=Amyloidosis%20and%20the%20heart:%20a%20comprehensive%20review&amp;author=KB%20Shah&amp;author=Y%20Inoue&amp;author=MR%20Mehra&amp;volume=166&amp;publication_year=2006&amp;pages=1805-1813&amp;pmid=17000935&amp;doi=10.1001/archinte.166.17.1805&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R9">
<span class="label">9.</span><cite>Desai HV, Aronow WS, Peterson SJ, Frishman WH. Cardiac amyloidosis: approaches to diagnosis and management. Cardiol Rev. 2010;18:1–11. doi: 10.1097/CRD.0b013e3181bdba8f.</cite> [<a href="https://doi.org/10.1097/CRD.0b013e3181bdba8f" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20010333/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiol%20Rev&amp;title=Cardiac%20amyloidosis:%20approaches%20to%20diagnosis%20and%20management&amp;author=HV%20Desai&amp;author=WS%20Aronow&amp;author=SJ%20Peterson&amp;author=WH%20Frishman&amp;volume=18&amp;publication_year=2010&amp;pages=1-11&amp;pmid=20010333&amp;doi=10.1097/CRD.0b013e3181bdba8f&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R10">
<span class="label">10.</span><cite>Westermark P, Sletten K, Johansson B, Cornwell GG., 3rd Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA. 1990;87:2843–2845. doi: 10.1073/pnas.87.7.2843.</cite> [<a href="https://doi.org/10.1073/pnas.87.7.2843" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC53787/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2320592/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20USA&amp;title=Fibril%20in%20senile%20systemic%20amyloidosis%20is%20derived%20from%20normal%20transthyretin&amp;author=P%20Westermark&amp;author=K%20Sletten&amp;author=B%20Johansson&amp;author=GG%20Cornwell&amp;volume=87&amp;publication_year=1990&amp;pages=2843-2845&amp;pmid=2320592&amp;doi=10.1073/pnas.87.7.2843&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R11">
<span class="label">11.</span><cite>Rapezzi C, et al.  Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7:398–408. doi: 10.1038/nrcardio.2010.67.</cite> [<a href="https://doi.org/10.1038/nrcardio.2010.67" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20479782/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Cardiol&amp;title=Transthyretin-related%20amyloidoses%20and%20the%20heart:%20a%20clinical%20overview&amp;author=C%20Rapezzi&amp;volume=7&amp;publication_year=2010&amp;pages=398-408&amp;pmid=20479782&amp;doi=10.1038/nrcardio.2010.67&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R12">
<span class="label">12.</span><cite>Jacobson DR, et al.  Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336:466–473. doi: 10.1056/NEJM199702133360703.</cite> [<a href="https://doi.org/10.1056/NEJM199702133360703" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9017939/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Variant-sequence%20transthyretin%20(isoleucine%20122)%20in%20late-onset%20cardiac%20amyloidosis%20in%20black%20Americans&amp;author=DR%20Jacobson&amp;volume=336&amp;publication_year=1997&amp;pages=466-473&amp;pmid=9017939&amp;doi=10.1056/NEJM199702133360703&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R13">
<span class="label">13.</span><cite>Jiang X, Buxbaum JN, Kelly JW. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci USA. 2001;98:14943–14948. doi: 10.1073/pnas.261419998.</cite> [<a href="https://doi.org/10.1073/pnas.261419998" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC64963/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11752443/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20USA&amp;title=The%20V122I%20cardiomyopathy%20variant%20of%20transthyretin%20increases%20the%20velocity%20of%20rate-limiting%20tetramer%20dissociation,%20resulting%20in%20accelerated%20amyloidosis&amp;author=X%20Jiang&amp;author=JN%20Buxbaum&amp;author=JW%20Kelly&amp;volume=98&amp;publication_year=2001&amp;pages=14943-14948&amp;pmid=11752443&amp;doi=10.1073/pnas.261419998&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R14">
<span class="label">14.</span><cite>Connors LH, et al.  Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J. 2009;158:607–614. doi: 10.1016/j.ahj.2009.08.006.</cite> [<a href="https://doi.org/10.1016/j.ahj.2009.08.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19781421/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20Heart%20J&amp;title=Cardiac%20amyloidosis%20in%20African%20Americans:%20comparison%20of%20clinical%20and%20laboratory%20features%20of%20transthyretin%20V122I%20amyloidosis%20and%20immunoglobulin%20light%20chain%20amyloidosis&amp;author=LH%20Connors&amp;volume=158&amp;publication_year=2009&amp;pages=607-614&amp;pmid=19781421&amp;doi=10.1016/j.ahj.2009.08.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R15">
<span class="label">15.</span><cite>Buxbaum J, et al.  Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J. 2010;159:864–870. doi: 10.1016/j.ahj.2010.02.006.</cite> [<a href="https://doi.org/10.1016/j.ahj.2010.02.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2865207/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20435197/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20Heart%20J&amp;title=Significance%20of%20the%20amyloidogenic%20transthyretin%20Val%20122%20Ile%20allele%20in%20African%20Americans%20in%20the%20Arteriosclerosis%20Risk%20in%20Communities%20(ARIC)%20and%20Cardiovascular%20Health%20(CHS)%20Studies&amp;author=J%20Buxbaum&amp;volume=159&amp;publication_year=2010&amp;pages=864-870&amp;pmid=20435197&amp;doi=10.1016/j.ahj.2010.02.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R16">
<span class="label">16.</span><cite>Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol. 2010;20:54–62. doi: 10.1016/j.sbi.2009.12.009.</cite> [<a href="https://doi.org/10.1016/j.sbi.2009.12.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2830738/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20133122/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Opin%20Struct%20Biol&amp;title=Structure-based%20design%20of%20kinetic%20stabilizers%20that%20ameliorate%20the%20transthyretin%20amyloidoses&amp;author=S%20Connelly&amp;author=S%20Choi&amp;author=SM%20Johnson&amp;author=JW%20Kelly&amp;author=IA%20Wilson&amp;volume=20&amp;publication_year=2010&amp;pages=54-62&amp;pmid=20133122&amp;doi=10.1016/j.sbi.2009.12.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R17">
<span class="label">17.</span><cite>Hammarstrom P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science. 2001;293:2459–2462. doi: 10.1126/science.1062245.</cite> [<a href="https://doi.org/10.1126/science.1062245" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11577236/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Trans-suppression%20of%20misfolding%20in%20an%20amyloid%20disease&amp;author=P%20Hammarstrom&amp;author=F%20Schneider&amp;author=JW%20Kelly&amp;volume=293&amp;publication_year=2001&amp;pages=2459-2462&amp;pmid=11577236&amp;doi=10.1126/science.1062245&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R18">
<span class="label">18.</span><cite>Hammarstrom P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 2003;299:713–716. doi: 10.1126/science.1079589.</cite> [<a href="https://doi.org/10.1126/science.1079589" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12560553/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Prevention%20of%20transthyretin%20amyloid%20disease%20by%20changing%20protein%20misfolding%20energetics&amp;author=P%20Hammarstrom&amp;author=RL%20Wiseman&amp;author=ET%20Powers&amp;author=JW%20Kelly&amp;volume=299&amp;publication_year=2003&amp;pages=713-716&amp;pmid=12560553&amp;doi=10.1126/science.1079589&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R19">
<span class="label">19.</span><cite><a href="http://clinicaltrials.gov/ct2/show/NCT00294671" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://clinicaltrials.gov/ct2/show/NCT00294671</a></cite>
</li>
<li id="R20">
<span class="label">20.</span><cite>Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302–1308. doi: 10.1136/bmj.332.7553.1302.</cite> [<a href="https://doi.org/10.1136/bmj.332.7553.1302" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1473048/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16740558/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=Do%20selective%20cyclo-oxygenase-2%20inhibitors%20and%20traditional%20non-steroidal%20anti-inflammatory%20drugs%20increase%20the%20risk%20of%20atherothrombosis?%20Meta-analysis%20of%20randomised%20trials&amp;author=PM%20Kearney&amp;author=C%20Baigent&amp;author=J%20Godwin&amp;author=H%20Halls&amp;author=JR%20Emberson&amp;volume=332&amp;publication_year=2006&amp;pages=1302-1308&amp;pmid=16740558&amp;doi=10.1136/bmj.332.7553.1302&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R21">
<span class="label">21.</span><cite>Epstein M. J. Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction. Hypertens. 2002;(Suppl 20):S17–23.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/12683423/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hypertens&amp;title=J.%20Non-steroidal%20anti-inflammatory%20drugs%20and%20the%20continuum%20of%20renal%20dysfunction&amp;author=M%20Epstein&amp;issue=Suppl%2020&amp;publication_year=2002&amp;pages=S17-23&amp;pmid=12683423&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R22">
<span class="label">22.</span><cite>Marnett LJ, Kalgutka AS. Cyclooxygenase 2 inhibitors: discovery, selectivity and the future. Trends Pharmacol Sci. 1999;20:465–469. doi: 10.1016/s0165-6147(99)01385-1.</cite> [<a href="https://doi.org/10.1016/s0165-6147(99)01385-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10542447/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Trends%20Pharmacol%20Sci&amp;title=Cyclooxygenase%202%20inhibitors:%20discovery,%20selectivity%20and%20the%20future&amp;author=LJ%20Marnett&amp;author=AS%20Kalgutka&amp;volume=20&amp;publication_year=1999&amp;pages=465-469&amp;pmid=10542447&amp;doi=10.1016/s0165-6147(99)01385-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R23">
<span class="label">23.</span><cite>Wallace JL. Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol. 2001;15:691–703. doi: 10.1053/bega.2001.0229.</cite> [<a href="https://doi.org/10.1053/bega.2001.0229" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11566035/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Best%20Pract%20Res%20Clin%20Gastroenterol&amp;title=Pathogenesis%20of%20NSAID-induced%20gastroduodenal%20mucosal%20injury&amp;author=JL%20Wallace&amp;volume=15&amp;publication_year=2001&amp;pages=691-703&amp;pmid=11566035&amp;doi=10.1053/bega.2001.0229&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R24">
<span class="label">24.</span><cite>Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954–959. doi: 10.1001/jama.286.8.954.</cite> [<a href="https://doi.org/10.1001/jama.286.8.954" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11509060/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Risk%20of%20cardiovascular%20events%20associated%20with%20selective%20COX-2%20inhibitors&amp;author=D%20Mukherjee&amp;author=SE%20Nissen&amp;author=EJ%20Topol&amp;volume=286&amp;publication_year=2001&amp;pages=954-959&amp;pmid=11509060&amp;doi=10.1001/jama.286.8.954&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R25">
<span class="label">25.</span><cite>Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000;160:777–784. doi: 10.1001/archinte.160.6.777.</cite> [<a href="https://doi.org/10.1001/archinte.160.6.777" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10737277/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Intern%20Med&amp;title=Consumption%20of%20NSAIDs%20and%20the%20development%20of%20congestive%20heart%20failure%20in%20elderly%20patients:%20an%20underrecognized%20public%20health%20problem&amp;author=J%20Page&amp;author=D%20Henry&amp;volume=160&amp;publication_year=2000&amp;pages=777-784&amp;pmid=10737277&amp;doi=10.1001/archinte.160.6.777&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R26">
<span class="label">26.</span><cite>Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77:1–16. doi: 10.1016/j.clpt.2004.08.009.</cite> [<a href="https://doi.org/10.1016/j.clpt.2004.08.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15637526/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Ther&amp;title=Clinical%20consequences%20of%20cytochrome%20P450%202C9%20polymorphisms&amp;author=J%20Kirchheiner&amp;author=J%20Brockm%C3%B6ller&amp;volume=77&amp;publication_year=2005&amp;pages=1-16&amp;pmid=15637526&amp;doi=10.1016/j.clpt.2004.08.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R27">
<span class="label">27.</span><cite>Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005;33:1567–1575. doi: 10.1124/dmd.105.006452.</cite> [<a href="https://doi.org/10.1124/dmd.105.006452" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16118328/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drug%20Metab%20Dispos&amp;title=Impact%20of%20CYP2C9%20genotype%20on%20pharmacokinetics:%20are%20all%20cyclooxygenase%20inhibitors%20the%20same?&amp;author=AD%20Rodrigues&amp;volume=33&amp;publication_year=2005&amp;pages=1567-1575&amp;pmid=16118328&amp;doi=10.1124/dmd.105.006452&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R28">
<span class="label">28.</span><cite>Prapunpoj P, Leelawatwatana L, Schreiber G, Richardson SJ. Change in structure of the N-terminal region of transthyretin produces change in affinity of transthyretin to T4 and T3. FEBS J. 2006;273:4013–4023. doi: 10.1111/j.1742-4658.2006.05404.x.</cite> [<a href="https://doi.org/10.1111/j.1742-4658.2006.05404.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16879610/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=FEBS%20J&amp;title=Change%20in%20structure%20of%20the%20N-terminal%20region%20of%20transthyretin%20produces%20change%20in%20affinity%20of%20transthyretin%20to%20T4%20and%20T3&amp;author=P%20Prapunpoj&amp;author=L%20Leelawatwatana&amp;author=G%20Schreiber&amp;author=SJ%20Richardson&amp;volume=273&amp;publication_year=2006&amp;pages=4013-4023&amp;pmid=16879610&amp;doi=10.1111/j.1742-4658.2006.05404.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R29">
<span class="label">29.</span><cite>Colon W, Kelly JW. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry. 1992;31:8654–8660. doi: 10.1021/bi00151a036.</cite> [<a href="https://doi.org/10.1021/bi00151a036" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1390650/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Partial%20denaturation%20of%20transthyretin%20is%20sufficient%20for%20amyloid%20fibril%20formation%20in%20vitro&amp;author=W%20Colon&amp;author=JW%20Kelly&amp;volume=31&amp;publication_year=1992&amp;pages=8654-8660&amp;pmid=1390650&amp;doi=10.1021/bi00151a036&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R30">
<span class="label">30.</span><cite>Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem. 2004;47:355–374. doi: 10.1021/jm030347n.</cite> [<a href="https://doi.org/10.1021/jm030347n" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14711308/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Med%20Chem&amp;title=Diflunisal%20analogues%20stabilize%20the%20native%20state%20of%20transthyretin.%20Potent%20inhibition%20of%20amyloidogenesis&amp;author=SL%20Adamski-Werner&amp;author=SK%20Palaninathan&amp;author=JC%20Sacchettini&amp;author=JW%20Kelly&amp;volume=47&amp;publication_year=2004&amp;pages=355-374&amp;pmid=14711308&amp;doi=10.1021/jm030347n&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R31">
<span class="label">31.</span><cite>Wiseman RL, et al.  Kinetic stabilization of an oligomeric protein by a single ligand binding event. J Am Chem Soc. 2005;127:5540–5551. doi: 10.1021/ja042929f.</cite> [<a href="https://doi.org/10.1021/ja042929f" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15826192/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Chem%20Soc&amp;title=Kinetic%20stabilization%20of%20an%20oligomeric%20protein%20by%20a%20single%20ligand%20binding%20event&amp;author=RL%20Wiseman&amp;volume=127&amp;publication_year=2005&amp;pages=5540-5551&amp;pmid=15826192&amp;doi=10.1021/ja042929f&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R32">
<span class="label">32.</span><cite>Threshold value: mean signal of negative/positive control plus/minus three times their standard deviation; Separation band (S): difference between the positive and negative thresholds values; Dynamic range (R): difference between the positive and negative means. Z-factor (= S/R): a value between 0.5 and 1 indicates an excellent screening assay.</cite>
</li>
<li id="R33">
<span class="label">33.</span><cite>Zhang JH, Chung TD, Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen. 1999;4:67–73. doi: 10.1177/108705719900400206.</cite> [<a href="https://doi.org/10.1177/108705719900400206" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10838414/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Biomol%20Screen&amp;title=A%20Simple%20Statistical%20Parameter%20for%20Use%20in%20Evaluation%20and%20Validation%20of%20High%20Throughput%20Screening%20Assays&amp;author=JH%20Zhang&amp;author=TD%20Chung&amp;author=KR%20Oldenburg&amp;volume=4&amp;publication_year=1999&amp;pages=67-73&amp;pmid=10838414&amp;doi=10.1177/108705719900400206&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R34">
<span class="label">34.</span><cite>Green NS, Foss TR, Kelly JW. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc Natl Acad Sci USA. 2005;102:14545–14550. doi: 10.1073/pnas.0501609102.</cite> [<a href="https://doi.org/10.1073/pnas.0501609102" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1253540/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16195386/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20USA&amp;title=Genistein,%20a%20natural%20product%20from%20soy,%20is%20a%20potent%20inhibitor%20of%20transthyretin%20amyloidosis&amp;author=NS%20Green&amp;author=TR%20Foss&amp;author=JW%20Kelly&amp;volume=102&amp;publication_year=2005&amp;pages=14545-14550&amp;pmid=16195386&amp;doi=10.1073/pnas.0501609102&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R35">
<span class="label">35.</span><cite>Borgulya J, Bruderer H, Bernauer K, Zürcher G, Da Prada M. Catechol-O-methyltransferase-Inhibiting Pyrocatechol Derivatives: Synthesis and Structure-Activity Studies. Helvetica Chimica Acta. 1989;72:952–968.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Helvetica%20Chimica%20Acta&amp;title=Catechol-O-methyltransferase-Inhibiting%20Pyrocatechol%20Derivatives:%20Synthesis%20and%20Structure-Activity%20Studies&amp;author=J%20Borgulya&amp;author=H%20Bruderer&amp;author=K%20Bernauer&amp;author=G%20Z%C3%BCrcher&amp;author=M%20Da%20Prada&amp;volume=72&amp;publication_year=1989&amp;pages=952-968&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R36">
<span class="label">36.</span><cite>Trivella DB, et al.  Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: Implications to tetramer stability and ligand-binding. J Struct Biol. 2010;170:522–531. doi: 10.1016/j.jsb.2010.03.002.</cite> [<a href="https://doi.org/10.1016/j.jsb.2010.03.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20211733/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Struct%20Biol&amp;title=Conformational%20differences%20between%20the%20wild%20type%20and%20V30M%20mutant%20transthyretin%20modulate%20its%20binding%20to%20genistein:%20Implications%20to%20tetramer%20stability%20and%20ligand-binding&amp;author=DB%20Trivella&amp;volume=170&amp;publication_year=2010&amp;pages=522-531&amp;pmid=20211733&amp;doi=10.1016/j.jsb.2010.03.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R37">
<span class="label">37.</span><cite>Leavitt S, Freire E. Direct measurement of protein binding energetics by isothermal titration calorimetry. Curr Opin Struct Biol. 2001;11:560–566. doi: 10.1016/s0959-440x(00)00248-7.</cite> [<a href="https://doi.org/10.1016/s0959-440x(00)00248-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11785756/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Opin%20Struct%20Biol&amp;title=Direct%20measurement%20of%20protein%20binding%20energetics%20by%20isothermal%20titration%20calorimetry&amp;author=S%20Leavitt&amp;author=E%20Freire&amp;volume=11&amp;publication_year=2001&amp;pages=560-566&amp;pmid=11785756&amp;doi=10.1016/s0959-440x(00)00248-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R38">
<span class="label">38.</span><cite>We note here that the ability of TTR to bind to two ligands complicates the analysis of our SPR data: in principle, there should be two on-rates and two off-rates for ligand binding, requiring a double exponential model to fit the data. Since we used monoexponentials, our reported rate constants should be considered estimates for the slower of the two binding and dissociation events.</cite>
</li>
<li id="R39">
<span class="label">39.</span><cite>Johnson SM, Connelly S, Wilson IA, Kelly JW. Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem. 2008;51:6348–6358. doi: 10.1021/jm800435s.</cite> [<a href="https://doi.org/10.1021/jm800435s" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2587341/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18811132/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Med%20Chem&amp;title=Toward%20optimization%20of%20the%20linker%20substructure%20common%20to%20transthyretin%20amyloidogenesis%20inhibitors%20using%20biochemical%20and%20structural%20studies&amp;author=SM%20Johnson&amp;author=S%20Connelly&amp;author=IA%20Wilson&amp;author=JW%20Kelly&amp;volume=51&amp;publication_year=2008&amp;pages=6348-6358&amp;pmid=18811132&amp;doi=10.1021/jm800435s&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R40">
<span class="label">40.</span><cite>Bourgault S, Choi S, Buxbaum JN, Kelly JW, Price JL, Reixach N. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem Biophys Res Commun. 2011 doi: 10.1016/j.bbrc.2011.04.133.</cite> [<a href="https://doi.org/10.1016/j.bbrc.2011.04.133" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3145458/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21557933/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochem%20Biophys%20Res%20Commun&amp;title=Mechanisms%20of%20transthyretin%20cardiomyocyte%20toxicity%20inhibition%20by%20resveratrol%20analogs&amp;author=S%20Bourgault&amp;author=S%20Choi&amp;author=JN%20Buxbaum&amp;author=JW%20Kelly&amp;author=JL%20Price&amp;publication_year=2011&amp;pmid=21557933&amp;doi=10.1016/j.bbrc.2011.04.133&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R41">
<span class="label">41.</span><cite>Davidson MM, et al.  Novel cell lines derived from adult human ventricular cardiomyocytes. J Mol Cell Cardiol. 2005;39:133–147. doi: 10.1016/j.yjmcc.2005.03.003.</cite> [<a href="https://doi.org/10.1016/j.yjmcc.2005.03.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15913645/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Mol%20Cell%20Cardiol&amp;title=Novel%20cell%20lines%20derived%20from%20adult%20human%20ventricular%20cardiomyocytes&amp;author=MM%20Davidson&amp;volume=39&amp;publication_year=2005&amp;pages=133-147&amp;pmid=15913645&amp;doi=10.1016/j.yjmcc.2005.03.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R42">
<span class="label">42.</span><cite>Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA. 2004;101:2817–2822. doi: 10.1073/pnas.0400062101.</cite> [<a href="https://doi.org/10.1073/pnas.0400062101" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC365703/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14981241/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20USA&amp;title=Tissue%20damage%20in%20the%20amyloidoses:%20Transthyretin%20monomers%20and%20nonnative%20oligomers%20are%20the%20major%20cytotoxic%20species%20in%20tissue%20culture&amp;author=N%20Reixach&amp;author=S%20Deechongkit&amp;author=X%20Jiang&amp;author=JW%20Kelly&amp;author=JN%20Buxbaum&amp;volume=101&amp;publication_year=2004&amp;pages=2817-2822&amp;pmid=14981241&amp;doi=10.1073/pnas.0400062101&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R43">
<span class="label">43.</span><cite>Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest. 2004;84:545–552. doi: 10.1038/labinvest.3700059.</cite> [<a href="https://doi.org/10.1038/labinvest.3700059" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14968122/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lab%20Invest&amp;title=Native%20state%20stabilization%20by%20NSAIDs%20inhibits%20transthyretin%20amyloidogenesis%20from%20the%20most%20common%20familial%20disease%20variants&amp;author=SR%20Miller&amp;author=Y%20Sekijima&amp;author=JW%20Kelly&amp;volume=84&amp;publication_year=2004&amp;pages=545-552&amp;pmid=14968122&amp;doi=10.1038/labinvest.3700059&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R44">
<span class="label">44.</span><cite>Jonsen E, Suhr OB, Tashima K, Athlin E. Early liver transplantation is essential for familial amyloidotic polyneuropathy patients’ quality of life. Amyloid. 2001;8:52–57. doi: 10.3109/13506120108993814.</cite> [<a href="https://doi.org/10.3109/13506120108993814" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11293825/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Early%20liver%20transplantation%20is%20essential%20for%20familial%20amyloidotic%20polyneuropathy%20patients%E2%80%99%20quality%20of%20life&amp;author=E%20Jonsen&amp;author=OB%20Suhr&amp;author=K%20Tashima&amp;author=E%20Athlin&amp;volume=8&amp;publication_year=2001&amp;pages=52-57&amp;pmid=11293825&amp;doi=10.3109/13506120108993814&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R45">
<span class="label">45.</span><cite>Hamour IM, et al.  Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis. Am J Transplant. 2008;8:1056–1059. doi: 10.1111/j.1600-6143.2008.02162.x.</cite> [<a href="https://doi.org/10.1111/j.1600-6143.2008.02162.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18318779/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Transplant&amp;title=Heart%20transplantation%20for%20homozygous%20familial%20transthyretin%20(TTR)%20V122I%20cardiac%20amyloidosis&amp;author=IM%20Hamour&amp;volume=8&amp;publication_year=2008&amp;pages=1056-1059&amp;pmid=18318779&amp;doi=10.1111/j.1600-6143.2008.02162.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R46">
<span class="label">46.</span><cite>Almeida MR, Gales L, Damas AM, Cardoso I, Saraiva MJ. Small transthyretin TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr Drug Targets CNS Neurol Disord. 2005;4:587–596. doi: 10.2174/156800705774322076.</cite> [<a href="https://doi.org/10.2174/156800705774322076" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16266291/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Drug%20Targets%20CNS%20Neurol%20Disord&amp;title=Small%20transthyretin%20TTR)%20ligands%20as%20possible%20therapeutic%20agents%20in%20TTR%20amyloidoses&amp;author=MR%20Almeida&amp;author=L%20Gales&amp;author=AM%20Damas&amp;author=I%20Cardoso&amp;author=MJ%20Saraiva&amp;volume=4&amp;publication_year=2005&amp;pages=587-596&amp;pmid=16266291&amp;doi=10.2174/156800705774322076&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R47">
<span class="label">47.</span><cite>McCutchen SL, Colon W, Kelly JW. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry. 1993;32:12119–12127. doi: 10.1021/bi00096a024.</cite> [<a href="https://doi.org/10.1021/bi00096a024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8218290/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Transthyretin%20mutation%20Leu-55-Pro%20significantly%20alters%20tetramer%20stability%20and%20increases%20amyloidogenicity&amp;author=SL%20McCutchen&amp;author=W%20Colon&amp;author=JW%20Kelly&amp;volume=32&amp;publication_year=1993&amp;pages=12119-12127&amp;pmid=8218290&amp;doi=10.1021/bi00096a024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R48">
<span class="label">48.</span><cite>Quintas A, Saraiva MJ, Brito RM. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Lett. 1997;418:297– 300. doi: 10.1016/s0014-5793(97)01398-7.</cite> [<a href="https://doi.org/10.1016/s0014-5793(97)01398-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9428731/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=FEBS%20Lett&amp;title=The%20amyloidogenic%20potential%20of%20transthyretin%20variants%20correlates%20with%20their%20tendency%20to%20aggregate%20in%20solution&amp;author=A%20Quintas&amp;author=MJ%20Saraiva&amp;author=RM%20Brito&amp;volume=418&amp;publication_year=1997&amp;pages=297-300&amp;pmid=9428731&amp;doi=10.1016/s0014-5793(97)01398-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R49">
<span class="label">49.</span><cite>Coelho T, et al.  A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR Met 30 and TTR Met 119. J Rheumatol. 1993;120:179.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Rheumatol&amp;title=A%20strikingly%20benign%20evolution%20of%20FAP%20in%20an%20individual%20found%20to%20be%20a%20compound%20heterozygote%20for%20two%20TTR%20mutations:%20TTR%20Met%2030%20and%20TTR%20Met%20119&amp;author=T%20Coelho&amp;volume=120&amp;publication_year=1993&amp;pages=179&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R50">
<span class="label">50.</span><cite>Kolstoe SE, Wood SP. Drug targets for amyloidosis. Biochem Soc Trans. 2010;38:466–470. doi: 10.1042/BST0380466.</cite> [<a href="https://doi.org/10.1042/BST0380466" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20298204/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochem%20Soc%20Trans&amp;title=Drug%20targets%20for%20amyloidosis&amp;author=SE%20Kolstoe&amp;author=SP%20Wood&amp;volume=38&amp;publication_year=2010&amp;pages=466-470&amp;pmid=20298204&amp;doi=10.1042/BST0380466&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R51">
<span class="label">51.</span><cite><a href="http://clinicaltrials.gov/ct2/show/" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://clinicaltrials.gov/ct2/show/</a> <a href="https://clinicaltrials.gov/ct2/show/NCT00409175" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT00409175</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT00791492" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT00791492</a></cite>
</li>
<li id="R52">
<span class="label">52.</span><cite>Yi S, Takahashi K, Naito M, Tashiro F, Wakasugi S, Maeda S, Shimada K, Yamamura K, Araki S. Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy, type I. Am J Pathol. 1991;138:403–12.</cite> [<a href="/articles/PMC1886191/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1992765/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Pathol&amp;title=Systemic%20amyloidosis%20in%20transgenic%20mice%20carrying%20the%20human%20mutant%20transthyretin%20(Met30)%20gene.%20Pathologic%20similarity%20to%20human%20familial%20amyloidotic%20polyneuropathy,%20type%20I&amp;author=S%20Yi&amp;author=K%20Takahashi&amp;author=M%20Naito&amp;author=F%20Tashiro&amp;author=S%20Wakasugi&amp;volume=138&amp;publication_year=1991&amp;pages=403-12&amp;pmid=1992765&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R53">
<span class="label">53.</span><cite>Kohno K, Palha JA, Miyakawa K, Saraiva MJ, Ito S, Mabuchi T, Blaner WS, Iijima H, Tsukahara S, Episkopou V, Gottesman ME, Shimada K, Takahashi K, Yamamura K, Maeda S. Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am J Pathol. 1997;150:1497–1508.</cite> [<a href="/articles/PMC1858187/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9095004/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Pathol&amp;title=Analysis%20of%20amyloid%20deposition%20in%20a%20transgenic%20mouse%20model%20of%20homozygous%20familial%20amyloidotic%20polyneuropathy&amp;author=K%20Kohno&amp;author=JA%20Palha&amp;author=K%20Miyakawa&amp;author=MJ%20Saraiva&amp;author=S%20Ito&amp;volume=150&amp;publication_year=1997&amp;pages=1497-1508&amp;pmid=9095004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R54">
<span class="label">54.</span><cite>Ingenbleek Y, Young V. Transthyretin (prealbumin) in health and disease: nutritional implications. Annu Rev Nutr. 1994;14:495–533. doi: 10.1146/annurev.nu.14.070194.002431.</cite> [<a href="https://doi.org/10.1146/annurev.nu.14.070194.002431" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7946531/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annu%20Rev%20Nutr&amp;title=Transthyretin%20(prealbumin)%20in%20health%20and%20disease:%20nutritional%20implications&amp;author=Y%20Ingenbleek&amp;author=V%20Young&amp;volume=14&amp;publication_year=1994&amp;pages=495-533&amp;pmid=7946531&amp;doi=10.1146/annurev.nu.14.070194.002431&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R55">
<span class="label">55.</span><cite>Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J.  Harrison’s Principles of Internal Medicine. 17. Vol. 1448. 2008. p. 1763.p. 1770.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Harrison%E2%80%99s%20Principles%20of%20Internal%20Medicine&amp;author=AS%20Fauci&amp;author=E%20Braunwald&amp;author=DL%20Kasper&amp;author=SL%20Hauser&amp;author=DL%20Longo&amp;publication_year=2008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p">
<span>Supplemental Information</span><p>Fig. S1. Calorimetric titration of ligands against TTR.</p>
<p>Fig. S2. Displacement FP assay of TTR ligands.</p>
<p>Fig. S3. Dynamic range and Z′ factor for the FP assay.</p>
<p>Fig. S4. Confirmation and assessment of ligands binding to TTR using SPR.</p>
<p>Fig. S5. <sup>1</sup>H NMR (chemical shifts and spectra), HRMS, and HPLC traces for HTS hits.</p>
<p>Fig. S6. Cartoon of TTR fibril formation assay.</p>
<p>Fig. S7. Calorimetric titration of ligands against TTR.</p>
<p>Fig. S8. Cytotoxicity of TTR ligands (8 μM) towards AC16 cardiac cells and inhibition of WT-TTR cytotoxicity towards IMR-32 neuroblastoma cells by the TTR ligands.</p>
<p>Fig. S9. Stabilization of serum TTR against acid-mediated denaturation.</p>
<p>Fig. S10. Fluorescence polarization of probe binding to human serum TTR.</p>
<p>Fig. S11. Structure and crystal packing of TTR in complex with <strong>14</strong>.</p>
<p>Table S1. Affinity of ligands as determined by ITC and FP.</p>
<p>Table S2. Chemical structures of TTR ligands. <sup>a</sup>TTR amyloidogenesis inhibition activity (%fibril formation). <sup>b</sup>IC<sub>50</sub> (compound concentration that resulted in 50% decrease in the FP signal).</p>
<p>Table S3. Isothermal Titration Calorimetry (ITC) analysis of ligands binding to human wild type TTR.</p>
<p>Table S4. X-ray data collection and refinement statistics.</p>
<p>Table S5. Summary of small molecule screening data.</p>
<p>Tables S6. Information summary about TTR FP Probe <strong>1</strong>.</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/3227540/bin/NIHMS337580-supplement-Supplemental_Information.pdf" data-ga-action="click_feat_suppl" class="usa-link">NIHMS337580-supplement-Supplemental_Information.pdf</a><sup> (4.6MB, pdf) </sup>
</div></div></section></section></section></section></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1126/scitranslmed.3002473"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/nihms337580.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.1 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/3227540/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/3227540/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC3227540%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC3227540/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC3227540/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC3227540/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/21865539/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC3227540/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/21865539/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC3227540/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/3227540/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="PNxECTosc0ZMZZNWJizxl4ltKz9eufVqQwkl5EME9meijs6hXwEd9IN3vnpO7PC4">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
